Inhibikase Therapeutics (IKT) Asset Utilization Ratio (2021 - 2024)
Inhibikase Therapeutics (IKT) reported Asset Utilization Ratio of 0.0 for Q3 2024, down 100.0% year-over-year from 0.02 in Q4 2023, and down 100.0% quarter-over-quarter from 0.01 in Q2 2024.
Inhibikase Therapeutics (IKT) Asset Utilization Ratio (2021 - 2024) Analysis & Trends
Inhibikase Therapeutics (IKT) has 4 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q3 2024.
- Asset Utilization Ratio for Q3 2024 came in at 0.0, down 100.0% year-over-year; the trailing twelve-month figure through Sep 2024 was 0.0 (down 100.0% YoY), and the FY2023 annual result was 0.01, up 260.65% from the prior year.
- Asset Utilization Ratio retreated to 0.0 in Q3 2024 per IKT's latest filing, from 0.01 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.14 in Q1 2021 and troughed at 0.0 in Q3 2024.
- A 4-year average of 0.03 and a median of 0.02 in 2024 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio soared 715.42% in 2023, then sank 100.0% in 2024.
- A 4-year view of Asset Utilization Ratio shows it stood at 0.07 in 2021, then slumped by 93.43% to 0.0 in 2022, then surged by 248.72% to 0.02 in 2023, then tumbled by 100.0% to 0.0 in 2024.
- Business Quant data shows IKT's Asset Utilization Ratio at 0.0 in Q3 2024, 0.01 in Q2 2024, and 0.02 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 0.55 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.60 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 1,422.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.01 |
| Mar 31, 2024 | 0.02 |
| Dec 31, 2023 | 0.02 |
| Sep 30, 2023 | 0.02 |
| Jun 30, 2023 | 0.01 |
| Mar 31, 2023 | 0.01 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.00 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | 0.04 |
| Dec 31, 2021 | 0.07 |
| Sep 30, 2021 | 0.07 |
| Jun 30, 2021 | 0.10 |
| Mar 31, 2021 | 0.14 |